"シオノギ" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonDrugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - Reuters
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion Reuters
Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma - Bloomberg.com
Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma Bloomberg.com
Shionogi Expands Pharmaceutical Capabilities with Strategic Acquisitions - TipRanks
Shionogi Expands Pharmaceutical Capabilities with Strategic Acquisitions TipRanks
Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal - Nikkei Asia
Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal Nikkei Asia
Japan's Shionogi to buy Torii Pharmaceutical for $1 billion, Nikkei says - TradingView
Japan's Shionogi to buy Torii Pharmaceutical for $1 billion, Nikkei says TradingView
Shionogi To Buy Torii Pharmaceutical For About 150 Billion Yen, Nikkei Says - marketscreener.com
Shionogi To Buy Torii Pharmaceutical For About 150 Billion Yen, Nikkei Says marketscreener.com
Shionogi & Co., Ltd.'s (TSE:4507) Stock Is Going Strong: Is the Market Following Fundamentals? - ...
Shionogi & Co., Ltd.'s (TSE:4507) Stock Is Going Strong: Is the Market Following Fundamentals? simplywall.st
Japan's Shionogi to acquire Torii Pharmaceutical from Japan Tobacco for $1 billion - MLex
Japan's Shionogi to acquire Torii Pharmaceutical from Japan Tobacco for $1 billion MLex
[JAPAN M&A] Shionogi (4507) Bids for Torii Pharma (4551) - Split Price Deal on Weak Transparency ...
[JAPAN M&A] Shionogi (4507) Bids for Torii Pharma (4551) - Split Price Deal on Weak Transparency Smartkarma
Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments - BioSpec...
Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments BioSpectrum Asia
Japan's drugmaker Shionogi to acquire JT's pharma units in $1bn deal - Nikkei Asia
Japan's drugmaker Shionogi to acquire JT's pharma units in $1bn deal Nikkei Asia
Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting...
Shionogi awarded $375m from HHS for preventative Covid-19 injectable - Pharmaceutical Technology
Shionogi awarded $375m from HHS for preventative Covid-19 injectable Pharmaceutical Technology
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults - Fierce Biotech
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults Fierce Biotech
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - GlobeNewswire
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia GlobeNewswire
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - marketscreen...
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion marketscreener.com
Shionogi to Announce Personnel Reassignment｜ 塩野義製薬 - Shionogi Inc.
Shionogi to Announce Personnel Reassignment｜ 塩野義製薬 Shionogi Inc.
Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome,...
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial - Clinical Trials A...
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial Clinical Trials Arena
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Reuters
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission Reuters
Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library ...
Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library | Shionogi & Co., Ltd. Shionogi Inc.
Shionogi's Strategies for Addressing Antibiotic Efficacy and Resistance - ContagionLive
Shionogi's Strategies for Addressing Antibiotic Efficacy and Resistance ContagionLive
Institutional owners may take dramatic actions as Shionogi & Co., Ltd.'s (TSE:4507) recent 7.5% d...
Institutional owners may take dramatic actions as Shionogi & Co., Ltd.'s (TSE:4507) recent 7.5% drop adds to one-year losses simplywall.st
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19...
Shionogi's RSV antiviral succeeds in mid-stage study - FirstWord Pharma
Shionogi's RSV antiviral succeeds in mid-stage study FirstWord Pharma
Shionogi gets approval in Japan for ADHD digital therapeutic - Pharmaphorum
Shionogi gets approval in Japan for ADHD digital therapeutic Pharmaphorum
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentation...
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan - GlobeNewswire
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan GlobeNewswire
Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants - BioWorld MedTech
Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants BioWorld MedTech
Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study - FirstWord Pharma
Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study FirstWord Pharma
David Benadon｜ 塩野義製薬 - Shionogi Inc.
David Benadon｜ 塩野義製薬 Shionogi Inc.
Shionogi to acquire full ownership of joint ventures with Ping An - The Pharma Letter
Shionogi to acquire full ownership of joint ventures with Ping An The Pharma Letter
Nxera and Shionogi launch Quviviq in Japan - The Pharma Letter
Nxera and Shionogi launch Quviviq in Japan The Pharma Letter
Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO - Eura...
Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO Euractiv
Notice of Head Office Relocation｜ 塩野義製薬 - Shionogi Inc.
Notice of Head Office Relocation｜ 塩野義製薬 Shionogi Inc.
Shionogi’s ensitrelvir prevents symptomatic COVID-19 - The Pharma Letter
Shionogi’s ensitrelvir prevents symptomatic COVID-19 The Pharma Letter
Antibiotics, an important but tricky business, says Shionogi CEO - Euractiv
Antibiotics, an important but tricky business, says Shionogi CEO Euractiv
Shionogi files NDA in Japan for zuranolone in MDD - The Pharma Letter
Shionogi files NDA in Japan for zuranolone in MDD The Pharma Letter
TABLE-Shionogi -2024/25 div forecast - TradingView
TABLE-Shionogi -2024/25 div forecast TradingView
Positive Phase III trial results for ensitrelvir - The Pharma Letter
Positive Phase III trial results for ensitrelvir The Pharma Letter
Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2 - Endpoints News
Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2 Endpoints News
Shionogi presents largest global real-world evidence study of cefiderocol - The Pharma Letter
Shionogi presents largest global real-world evidence study of cefiderocol The Pharma Letter
BARDA to fund development of COVID preventive drug - CIDRAP
Shionogi’s cefiderocol shows improved outcomes with early use in treating gram-negative infection...
Shionogi’s cefiderocol shows improved outcomes with early use in treating gram-negative infections: GlobalData Express Pharma
Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand - BioSpectrum Asia
Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand BioSpectrum Asia
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 - Shionogi Inc.
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 Shionogi Inc.
Shionogi’s Ensitrelvir Shows Promise in COVID-19 Prevention - TipRanks
Shionogi’s Ensitrelvir Shows Promise in COVID-19 Prevention TipRanks
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout - biocentury.com
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout biocentury.com
The Leadership Connection - BOSS Magazine
The Leadership Connection BOSS Magazine
Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Q...
Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego - Genetic Engineering and Biotechnology...
Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego Genetic Engineering and Biotechnology News
Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city re...
Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city resilient to infectious diseases BioSpectrum Asia
Global study shows cefiderocol’s success in treating resistant infections - European Pharmaceutic...
Global study shows cefiderocol’s success in treating resistant infections European Pharmaceutical Manufacturer
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Addre...
China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi - Yicai
China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi Yicai
Antiviral Prevents Symptomatic COVID-19 in Post-Exposure Prophylactic Study - ContagionLive
Antiviral Prevents Symptomatic COVID-19 in Post-Exposure Prophylactic Study ContagionLive
Shionogi - Technology Magazine
Shionogi Technology Magazine
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models - BioWorld MedTech
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models BioWorld MedTech
Shionogi's RSV antiviral shows promise in hVIVO trial - Investing.com
Shionogi's RSV antiviral shows promise in hVIVO trial Investing.com
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment - The Hearing Review
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment The Hearing Review
Japan's Shionogi seeks China approval for superbug-fighting antibiotic - Nikkei Asia
Japan's Shionogi seeks China approval for superbug-fighting antibiotic Nikkei Asia
APAC Healthcare Weekly (April 6)- Nippon Shinyaku, Shionogi, Beigene, Celltrion, Mesoblast, Lupin...
APAC Healthcare Weekly (April 6)- Nippon Shinyaku, Shionogi, Beigene, Celltrion, Mesoblast, Lupin Smartkarma
APAC Healthcare Weekly (Mar 30)- Eisai, Kaken, Mochida, Shionogi, SK Bioscience, PharmaEssentia -...
APAC Healthcare Weekly (Mar 30)- Eisai, Kaken, Mochida, Shionogi, SK Bioscience, PharmaEssentia Smartkarma
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial Reuters
hVIVO PLC (AIM:HVO) Shionogi reports positive RSV trial results - Share Talk
hVIVO PLC (AIM:HVO) Shionogi reports positive RSV trial results Share Talk
Shionogi's antiviral comes up short in global COVID-19 trial - Fierce Pharma
Shionogi's antiviral comes up short in global COVID-19 trial Fierce Pharma
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M - Fierce Biotech
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M Fierce Biotech
Shionogi secures license for Maze’s Pompe disease treatment - Pharmaceutical Technology
Shionogi secures license for Maze’s Pompe disease treatment Pharmaceutical Technology
hVIVO's human challenge trial shows strong results for Shionogi's RSV antiviral - Proactive Inves...
hVIVO's human challenge trial shows strong results for Shionogi's RSV antiviral Proactive Investors
SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...
Shionogi’s COVID-19 drug misses endpoint in global phase III - BioWorld MedTech
Shionogi’s COVID-19 drug misses endpoint in global phase III BioWorld MedTech
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 National Institutes of Health (NIH) (.gov)
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline - BioSpace
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline BioSpace
Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Mat...
Maze lands new partner for Pompe drug, after Sanofi pact came apart - BioPharma Dive
Maze lands new partner for Pompe drug, after Sanofi pact came apart BioPharma Dive
“Pharmaceutical Education” by Virtual Employee - Shionogi Inc.
“Pharmaceutical Education” by Virtual Employee Shionogi Inc.
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for...
Japan Aims to Cut Antibiotics Reliance on China by Resuming API Production - JAPAN Forward
Japan Aims to Cut Antibiotics Reliance on China by Resuming API Production JAPAN Forward
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss - BioSpectrum ...
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss BioSpectrum Asia
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value Shionogi Inc.
After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug - sta...
After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug statnews.com
Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Co...
Shionogi to acquire Qpex Biopharma for $140m - Pharmaceutical Technology
Shionogi to acquire Qpex Biopharma for $140m Pharmaceutical Technology
Shimadzu, Shionogi unveil international wastewater-based epidemiology lab at University of Tokyo,...
Shimadzu, Shionogi unveil international wastewater-based epidemiology lab at University of Tokyo, Japan BioSpectrum Asia
What we stand for: Takeki Uehara - Shionogi Inc.
What we stand for: Takeki Uehara Shionogi Inc.
Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacteri...
Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries Clinton Health Access Initiative
Japan's Shionogi seeks approval for COVID-19 pill - Reuters
Shionogi sinks in Tokyo trade after panel again delays COVID pill approval - Reuters
Shionogi sinks in Tokyo trade after panel again delays COVID pill approval Reuters
Shionogi reports data from Phase III portion of Covid-19 drug trial - Clinical Trials Arena
Shionogi reports data from Phase III portion of Covid-19 drug trial Clinical Trials Arena
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval - Reuters
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval Reuters
Zuranolone to face challenges in Japan’s MDD market despite demonstrating rapid onset of action: ...
Zuranolone to face challenges in Japan’s MDD market despite demonstrating rapid onset of action: GlobalData Express Pharma
Shionogi gains rights to Maze’s investigational Pompe disease therapy for $150m upfront - PMLiVE
Shionogi gains rights to Maze’s investigational Pompe disease therapy for $150m upfront PMLiVE
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine - Fierc...
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine Fierce Biotech
Japan's Shionogi says COVID-19 pill shows rapid clearance of virus - Reuters
Japan's Shionogi says COVID-19 pill shows rapid clearance of virus Reuters
Message from Top Management - Shionogi Inc.
Message from Top Management Shionogi Inc.
History - Shionogi Inc.
History Shionogi Inc.
F2G and Shionogi Present Full Data Set from Pivotal Phase - GlobeNewswire
F2G and Shionogi Present Full Data Set from Pivotal Phase GlobeNewswire
FDA declines to approve Shionogi, F2G's antifungal olorofim - FirstWord Pharma
FDA declines to approve Shionogi, F2G's antifungal olorofim FirstWord Pharma
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's lat...
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest move The Business Journals
Shionogi Announces Agreement With SOBI - European Pharmaceutical Manufacturer
Shionogi Announces Agreement With SOBI European Pharmaceutical Manufacturer